Literature DB >> 15639722

Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients.

Kazuya Takamochi1, Junji Yoshida, Koji Murakami, Seiji Niho, Genichiro Ishii, Mitsuyo Nishimura, Yutaka Nishiwaki, Kazuya Suzuki, Kanji Nagai.   

Abstract

BACKGROUND: The evidence of clinical value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) in lymph node (LN) staging in non-small cell lung cancer (NSCLC) has been shown in numerous papers. However, few studies have assessed its limitations. The aim of the present study is to clarify clinico-pathologic factors responsible for false PET results.
METHODS: From July 2000 through December 2001, 71 NSCLC patients underwent both FDG PET and surgical intervention at the National Cancer Center Hospital East, Chiba. Clinical records, computed tomographic (CT) scan findings, PET findings, and histologic findings were retrospectively reviewed.
RESULTS: Sensitivity, specificity, accuracy in nodal staging for CT were 29, 83, and 65% and for PET were 39, 79, and 66%, respectively. There were 10 (14%) false-positive PET scans and 14 (20%) false-negative PET scans. The causative factors for false-positive PET scan were: (1) inflammatory conditions in seven patients; (2) PET mis-localization of an interlobar LN as a mediastinal LN in one patient; (3) inability to distinguish the endobronchial polypoid growth of a primary tumor from a lobar LN in one patient; (4) unknown in one patient. All false-positive LNs due to inflammatory conditions showed reactive lymphoid hyperplasia histologically. The causative factors for false-negative PET scan were: (1) limitation of spatial resolution of the PET scanner in 12 patients (maximum tumor focus dimensions in false-negative LNs ranging from 1 to 7.5 mm, with an average of 3.4 mm); (2) PET mis-localization of a mediastinal LN as a hilar LN in one patient; (3) weak FDG uptake by microscopic tumor foci due to necrosis with massive bleeding in a metastatic LN in one patient.
CONCLUSIONS: Inflammatory conditions were most responsible for false-positive PET scans, and spatial resolution limitation of FDG PET was the causative factor of false-negative PET scans. Recognizing these factors in advance would be clinically helpful in accurate nodal staging with FDG PET.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15639722     DOI: 10.1016/j.lungcan.2004.08.004

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  21 in total

1.  [(18)F]-FDG PET/CT imaging for detection of nodal metastases in patients with squamous cell carcinoma of the pharynx and larynx: comparison with CT.

Authors:  Yuko Suenaga; Kazuhiro Kitajima; Tomonori Kanda; Naoki Otsuki; Ken-Ichi Nibu; Ryohei Sasaki; Tomoo Itoh; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-12-15       Impact factor: 2.374

2.  Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer.

Authors:  Haruhiko Nakamura; Masahiko Taguchi; Hajime Kitamura; Junichi Nishikawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-08-13

3.  Accuracy of positron emission tomography and computed tomography (PET/CT) in detecting nodal metastasis according to histology of non-small cell lung cancer.

Authors:  David E Smith; Julian Fernandez Aramburu; Alejandro Da Lozzo; Juan A Montagne; Enrique Beveraggi; Agustin Dietrich
Journal:  Updates Surg       Date:  2019-09-24

Review 4.  Imaging the lymphatic system.

Authors:  Lance L Munn; Timothy P Padera
Journal:  Microvasc Res       Date:  2014-06-21       Impact factor: 3.514

5.  Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis.

Authors:  Tomohiro Haruki; Makoto Wakahara; Yuki Matsuoka; Ken Miwa; Kunio Araki; Yuji Taniguchi; Hiroshige Nakamura
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-05-23       Impact factor: 1.520

6.  Usefulness of the neutrophil-to-lymphocyte ratio in predicting lymph node metastasis in patients with non-small cell lung cancer.

Authors:  Chongbiao Huang; Jie Yue; Zengxun Li; Na Li; Jinkun Zhao; Daliang Qi
Journal:  Tumour Biol       Date:  2015-04-29

7.  Heterogeneity Analysis of (18)F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting.

Authors:  Hendra Budiawan; Gi Jeong Cheon; Hyung-Jun Im; Soo Jin Lee; Jin Chul Paeng; Keon Wook Kang; June-Key Chung; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2013-08-21

8.  Dual-time-point FDG PET/CT: Is It Useful for Lymph Node Staging in Patients with Non-Small-Cell Lung Cancer?

Authors:  Dae-Weung Kim; Woo Hyoung Kim; Chang Guhn Kim
Journal:  Nucl Med Mol Imaging       Date:  2012-06-05

9.  18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort?

Authors:  Ruoh-Fang Yen; Ke-Cheng Chen; Jang-Ming Lee; Yeun-Chung Chang; Jane Wang; Mei-Fang Cheng; Yen-Wen Wu; Yung-Chie Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-19       Impact factor: 9.236

10.  Diagnostic performance of (18)F-FDG PET/CT for lymph node staging in patients with operable non-small-cell lung cancer and inflammatory lung disease.

Authors:  Young-Sil An; Joo Sung Sun; Kyung Joo Park; Sung Chul Hwang; Kwang Joo Park; Seung Soo Sheen; Sungsoo Lee; Kyi Beom Lee; Joon-Kee Yoon
Journal:  Lung       Date:  2008-08-01       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.